Literature DB >> 15675543

Iron overload and tuberculosis: a case for iron chelation therapy.

L Cronje1, L Bornman.   

Abstract

Elevated levels of iron impair immune defence mechanisms, and specifically the macrophage function of innate immunity. Iron enhances Mycobacterium tuberculosis infection, M. tuberculosis replication, progression to clinical disease and death from tuberculosis (TB). Chelation of iron in individuals with an excessive iron burden may reduce M. tuberculosis viability and replication, restore host defence mechanisms and could find application in the prevention and treatment strategies in settings where both iron overload and TB are prevalent. The objective of this paper was to summarise recent literature on the role of iron in TB pathogenesis and to examine the potential of iron chelation therapy. The literature confirms a key role for iron in mycobacterial virulence. The ability of chelation to enhance host effector mechanisms and to inhibit replication of various pathogens justifies further studies into iron chelation as a potential additive therapy for TB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15675543

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

Review 1.  Iron Homeostasis in Mycobacterium tuberculosis: Mechanistic Insights into Siderophore-Mediated Iron Uptake.

Authors:  Manjula Sritharan
Journal:  J Bacteriol       Date:  2016-08-25       Impact factor: 3.490

2.  Fluorescent 3-hydroxy-4-pyridinone hexadentate iron chelators: intracellular distribution and the relevance to antimycobacterial properties.

Authors:  Ana Nunes; Maria Podinovskaia; Andreia Leite; Paula Gameiro; Tao Zhou; Yongmin Ma; Xiaole Kong; Ulrich E Schaible; Robert C Hider; Maria Rangel
Journal:  J Biol Inorg Chem       Date:  2010-04-03       Impact factor: 3.358

Review 3.  The Impact of Dietary Transition Metals on Host-Bacterial Interactions.

Authors:  Christopher A Lopez; Eric P Skaar
Journal:  Cell Host Microbe       Date:  2018-06-13       Impact factor: 21.023

4.  The prevalence and evolution of anemia associated with tuberculosis.

Authors:  Sei Won Lee; Young Ae Kang; Young Soon Yoon; Sang-Won Um; Sang Min Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

Review 5.  Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.

Authors:  H Joachim Deeg; Emily Spaulding; Howard M Shulman
Journal:  Leuk Lymphoma       Date:  2009-10

6.  Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial Fe-dependent enzymes.

Authors:  Oyebode Olakanmi; Banurekha Kesavalu; Rajamouli Pasula; Maher Y Abdalla; Larry S Schlesinger; Bradley E Britigan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

7.  Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.

Authors:  Samantha Ellis; Danuta S Kalinowski; Lisa Leotta; Michael L H Huang; Peter Jelfs; Vitali Sintchenko; Des R Richardson; James A Triccas
Journal:  Mol Pharmacol       Date:  2013-11-15       Impact factor: 4.436

8.  Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.

Authors:  Karuna Gokarn; Ramprasad B Pal
Journal:  BMC Complement Altern Med       Date:  2017-03-21       Impact factor: 3.659

9.  Insights on the relationship between structure vs. toxicological activity of antibacterial rhodamine-labelled 3-hydroxy-4-pyridinone iron(III) chelators in HepG2 cells.

Authors:  Tânia Moniz; Diana Dias da Silva; Helena Carmo; Baltazar de Castro; Maria de Lourdes Bastos; Maria Rangel
Journal:  Interdiscip Toxicol       Date:  2019-10-18

Review 10.  Tuning the Anti(myco)bacterial Activity of 3-Hydroxy-4-pyridinone Chelators through Fluorophores.

Authors:  Maria Rangel; Tânia Moniz; André M N Silva; Andreia Leite
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.